

HETEROCYCLES, Vol. 85, No. 10, 2012, pp. 2543 - 2550. © 2012 The Japan Institute of Heterocyclic Chemistry
Received, 31st July, 2012, Accepted, 23rd August, 2012, Published online, 27th August, 2012
DOI: 10.3987/COM-12-12560

STEREOSPECIFIC SYNTHESIS OF *trans*-1,4-DIPHOSPHACYCLO- HEXANES

Yasuhiro Morisaki,* Hiroaki Imoto, Ryosuke Kato, Yuko Ouchi, and
Yoshiki Chujo*

Department of Polymer Chemistry, Graduate School of Engineering, Kyoto
University, Katsura, Nishikyo-ku, Kyoto 615-8510, Japan; E-mail:
ymo@chujo.synchem.kyoto-u.ac.jp, chujo@chujo.synchem.kyoto-u.ac.jp

Abstract — Stereospecific synthesis of *trans*-1,4-diphosphacyclohexanes via intramolecular oxidative coupling of P-stereogenic bisphosphine borane complexes is reported. Regardless of the enantiopurity of the starting materials, only *trans*-isomers were formed. The synthesis and characterization of the obtained products are described in detail herein.

Phosphines (trivalent organophosphorus compounds; PR_3 ; R = organic moiety), similar to tertiary amines (NR_3), have a trigonal pyramidal structure with the phosphorus atom at the apex; however, the inversion energy of PR_3 is much higher because of the increased *s* character resulting from the unshared electron pair on phosphorus.¹ Therefore, the phosphorus atom behaves as a chiral center in the same manner as a chiral carbon atom, and optically active phosphines are conformationally stable. From this structural viewpoint, a large number of optically active P-stereogenic phosphines have been synthesized;² in particular, optically active P-stereogenic bisphosphines have been widely used as chiral ligands for transition-metal-catalyzed asymmetric reactions.³ One such bisphosphine with a methyl substituent at each phosphorus atom, BisP* (Figure 1), was synthesized with relatively high enantiomeric excess (*ee*%) by Evans⁴ and Imamoto.⁵ In this study, we investigated the reactivity of BisP*–borane complexes and the feasibility of using BisP* as chiral building blocks for a variety of P-stereogenic compounds. Lithiation of the methyl group of BisP* by alkyllithium reagents proceeds smoothly because of the strong electron-withdrawing character of the coordinated borane. Actually, the BisP*–boranes can also be prepared by the lithiation of methylphosphine boranes or methylphosphine sulfides.^{4,5} Lithiation of BisP*–boranes and successive oxidative coupling affords various optically active P-stereogenic oligomers⁶ and polymers.⁷





Figure 1. Structures of BisP*–BH₃ complexes


We found that intramolecular oxidative coupling of the lithiated BisP*–boranes afforded *trans*-diphosphacyclohexanes in a stereospecific manner,⁸ which is the rare example of the stereo-controlled synthesis of *cis*- or *trans*-diphosphacycloalkanes. Alder and coworkers succeeded in the stereoselective synthesis of a series of *cis*-diphosphacycloalkanes by the ring-opening reaction of the corresponding bicyclic compounds.⁹ Recently, Strohmann and coworkers reported the synthesis of *trans*-1,4-diphenyl-1,4-diphosphacyclohexane by the direct dilithiation of prochiral dimethylphenylphosphine borane and its one-pot oxidative coupling reaction.¹⁰ Our synthetic route is attractive in that the only *trans*-isomer can be obtained from BisP*–borane, regardless of the enantiopurity of the starting material. For the purpose of establishing the synthetic method for the stereospecific synthesis of *trans*-1,4-diphosphacyclohexanes, we carried out the synthesis of *trans*-1,4-diphosphacyclohexanes from several optically active BisP*–boranes and characterized the products in detail.

The synthesis of *trans*-1,4-diphosphacyclohexanes commenced with optically active BisP*–boranes (*S,S*)-**1a-f**–BH₃, as shown in Scheme 1. Treatment of (*S,S*)-**1a-f**–BH₃ with *sec*-BuLi and amine ligands such as *N,N,N',N'*-tetramethylethylenediamine (TMEDA) and (–)-sparteine afforded a dilithiated intermediate. Transmetalation from Li to Cu using CuCl₂ and successive reductive elimination with aqueous NH₃ caused intramolecular oxidative coupling to provide the corresponding 1,4-diphosphacyclohexanes *trans*-**2a-f**–BH₃. The crude products were purified by SiO₂ column chromatography and recrystallized from hot toluene and hexane to give the desired products in moderate-to-good isolated yields. In this reaction, cyclization proceeded dominantly without polymeric compounds even in dilute solution, and the main by-product was the starting material.



Scheme 1

The stereochemistry of the obtained 1,4-diphosphacyclohexanes was completely “*trans*”; the reaction afforded only *trans*-isomers, because the reaction proceeded stereospecifically due to the use of enantiopure (*S,S*)-BisP*–boranes. In this stereospecific reaction, we do not need take care of the enantiopurity of the starting BisP*–boranes; in other words, BisP*–boranes with poor *ee*% as well as even *racemi*-BisP*–boranes provide only the *trans*-1,4-diphosphacyclohexanes, as shown in Scheme 2. (*S,S*)-BisP*–boranes could be readily obtained with high *ee*% by the intermolecular oxidative dimerization of RMe₂P–BH₃ using *sec*-BuLi and a chiral amine ligand such as (–)-sparteine; however, *meso*-BisP*–boranes formed in the reaction had to be removed from the reaction mixture since they would stereospecifically yield *cis*-1,4-diphosphacyclohexanes. Oxidative coupling of the mixture of *rac*- and *meso*-BisP*–boranes afforded equimolar amounts of *trans*- and *cis*-1,4-diphosphacyclohexane boranes, which could be separated by column chromatography, as shown in Scheme S1 (Supporting Information).



Scheme 2





Figure 2. ORTEP drawings of *trans-2a-f*-BH₃. Thermal ellipsoids are shown at the 30% probability level, and all hydrogen atoms are omitted for clarity

All the *trans-2a-f*-BH₃ compounds prepared were purified by recrystallization from hot toluene and hexane. Their structures were confirmed by ¹H, ¹³C, and ³¹P NMR, high-resolution mass analysis, elemental analysis, and X-ray crystallography. The ORTEP drawings of *trans-2a-f*-BH₃ are shown in Figure 2, and the crystallographic data are listed in Tables S1–S6 (Supporting Information). X-Ray crystallographic analysis revealed that *trans-2a-f*-BH₃ adopted a chair conformation with equatorial alkyl (and aryl) substituents and axial boranes in the crystal state.

We confirmed that the coordinated boranes could be removed from the *trans*-1,4-diphosphacyclohexane-borane complexes to obtain *trans*-1,4-diphosphacyclohexanes. Scheme 3 shows the removal of boranes of *trans-2a*- and **2d**-BH₃ as representative examples of aryl- and alkyl-substituted compounds, respectively. Generally, the removal of boranes of trialkylphosphine requires a relatively severe reaction conditions because of the strong phosphorus–boron coordination bond. Treatment of *trans-2d*-BH₃ with excess CF₃SO₃H and then with KOH afforded *trans-2d* in 91% isolated yield.¹¹ On the other hand, boranes of *trans-2a*-BH₃ were readily removed by the reaction with an organic base such as 1,4-diazabicyclo[2.2.2]octane (DABCO) to afford the corresponding bisphosphine *trans-2a* in 94% isolated yield.



Scheme 3

In conclusion, we demonstrated that *trans*-1,4-diphosphacyclohexanes can be stereospecifically prepared via the intramolecular oxidative coupling of optically active bisphosphine BisP*–boranes. Only *trans*-1,4-diphosphacyclohexane skeletons were formed, regardless of the enantiopurity of the BisP*–boranes. We showed the generality of our original synthetic method for the formation of *trans*-1,4-diphosphacyclohexanes with various substituents. Enantiopure BisP*s have been employed only as chiral ligands for transition metal-catalyzed asymmetric reactions; the results of this study reveal an entirely new set of applications of BisP* as chiral building blocks for a variety of P-stereogenic phosphorus compounds.

EXPERIMENTAL

^1H (400 MHz) and ^{13}C (100 MHz) NMR spectra were recorded on a JEOL EX400 or AL400 instrument. Samples were analyzed in CDCl_3 , and the chemical shift values were expressed relative to Me_4Si as an internal standard. ^{31}P NMR spectra were recorded on a JEOL EX400 spectrometer at 161.9 MHz, and samples were analyzed in CDCl_3 using H_3PO_4 as an external standard. Mass analysis was performed at technical support office at Department of Synthetic Chemistry and Biological Chemistry, Kyoto University; high-resolution mass spectra (HRMS) were obtained on a JEOL JMS-SX102A spectrometer for EI, JEOL JMS-HX110A for FAB, and Thermo Scientific EXACTIVE for ESI. Analytical thin layer chromatography (TLC) was performed with silica gel 60 Merck F254 plates. Column chromatography was performed with Wakogel C-300 SiO_2 . Elemental analysis was performed at the Microanalytical Center of Kyoto University.

Materials. THF was purchased and purified by passage through purification column under Ar pressure.¹² Dehydrated grade solvents of toluene and CHCl_3 were purchased and used without further purification. *N,N,N',N'*-Tetramethylethylenediamine (TMEDA) and (–)-sparteine were purchased and distilled from KOH under Ar atmosphere. *sec*-BuLi (1.0 M in cyclohexane and n-hexane solution), 1,4-diazabicyclo[2.2.2]octane (DABCO), CuCl_2 , aqueous NH_3 (28%) were purchased and used without purification. All (*S,S*)-BisP* borane complexes — (*S,S*)-**1a**– BH_3 ,⁴ (*S,S*)-**1b**– BH_3 ,⁴ (*S,S*)-**1c**– BH_3 ,¹³ (*S,S*)-**1d**– BH_3 ,⁵ (*S,S*)-**1e**– BH_3 ,⁵ and (*S,S*)-**1f**– BH_3 ⁵ — were prepared by the literature's procedures.

Reactions were performed under Ar atmosphere using standard Schlenk techniques.

Synthesis. Typical procedure is as follows. A solution of (–)-sparteine (0.55 mL, 2.5 mmol) as a ligand in THF (10 mL) was cooled to $-78\text{ }^{\circ}\text{C}$. To this solution, *sec*-BuLi (1.0 M in cyclohexane and *n*-hexane solution, 2.5 mL, 2.5 mmol) was added by a syringe. After 15 min, a solution of (*S,S*)-**1a**-BH₃ (0.302 g, 1.0 mmol) in THF (10 mL) was added dropwise, and the mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 3 h. CuCl₂ (0.270 g, 2.0 mmol) was added in one portion with vigorous stirring, and the mixture was allowed to slowly warm to room temperature. After 15 h, aqueous NH₃ (10 mL) was added, and the organic species were extracted with CH₂Cl₂ (3 × 10 mL). The combined extracts were washed with 5% aqueous NH₃, 2 N HCl, and brine, and then dried over MgSO₄. After evaporation of the solvent, the residue was purified by column chromatography on SiO₂ with hexane-CH₂Cl₂ (v/v = 1:1) and recrystallization from hot toluene-hexane to obtain *trans*-**2a**-BH₃ (167 mg, 0.56 mmol) as a colorless solid.

***trans*-2a-BH₃:** CCDC # 888064; 56% isolated yield; $R_f = 0.83$ (CH₂Cl₂ 100%, SiO₂); ¹H NMR (CDCl₃, 400 MHz) δ 0.87 (br q, $J_{\text{HB}} = 108.4\text{ Hz}$, -BH₃, 6H), 2.19 (dd, $J = 10.5\text{ Hz}$, $J_{\text{HP}} = 21.4\text{ Hz}$, -PCH₂-, 4H), 2.81 (m, -PCH₂-, 4H), 7.56 (m, -Ar, 6H) 7.88 (m, -Ar, 4H) ppm; ¹³C NMR (CDCl₃, 100 MHz) δ 19.7 (d, $J_{\text{CP}} = 33.7\text{ Hz}$, -PCH₂-), 127.3-132.2 (m, -Ar) ppm; ³¹P{¹H}NMR (CDCl₃, 161.9 MHz) δ +6.3 ppm. HRMS (EI). Calcd for C₁₆H₂₄B₂P₂ [M]⁺: 300.1539. Found 300.1532. Anal. Calcd for C₁₆H₂₄B₂P₂: C, 64.07; H, 8.07. Found: C, 63.85; H, 7.97.

***trans*-2b-BH₃:** CCDC # 888063; 30% isolated yield; $R_f = 0.5$ (hexane/EtOAc: v/v = 4:1, SiO₂); ¹H NMR (CDCl₃, 400 MHz) δ 0.91 (br q, $J_{\text{HB}} = 123.0\text{ Hz}$, -BH₃, 6H), 2.04 (m, P-CH₂-, 4H), 3.43 (m, P-CH₂, 4H), 4.05 (s, -CH₃, 6H), 6.99 (d, $J = 8.6\text{ Hz}$, -Ar, 2H), 7.10 (t, $J = 7.3\text{ Hz}$, -Ar, 2H), 7.56 (t, $J = 7.3\text{ Hz}$, -Ar, 2H), 8.00 (q, $J = 4.8\text{ Hz}$, -Ar, 2H) ppm; ¹³C NMR (CDCl₃, 100 MHz) δ 17.0 (d, $J_{\text{CP}} = 34.6\text{ Hz}$, -PCH₂-), 55.6 (s, -OCH₃), 110.7, 120.9, 134.1, 136.4, 136.5 and 162.0 (-Ar) ppm; ³¹P{¹H}NMR (CDCl₃, 161.9 MHz) δ +6.6 ($J_{\text{PB}} = 60.5\text{ Hz}$) ppm. HRMS (ESI). Calcd for C₁₈H₂₈B₂O₂P₂ [M+Na]⁺: 383.1643. Found 383.1638. Anal. Calcd for C₁₈H₂₈B₂O₂P₂: C, 60.06; H, 7.84. Found: C, 59.89; H, 8.11.

***trans*-2c-BH₃:** CCDC # 888062; 44% isolated yield; ¹H NMR (CDCl₃, 400 MHz) δ 0.39 (br q, $J_{\text{HB}} = 100.6\text{ Hz}$, -BH₃, 6H), 1.19 (q, $J = 8.3\text{ Hz}$, -(CH₃)₂, 12H), 1.88-2.03 (m, -PCH₂- and -CH(CH₃)₂, 6H), 2.24 (m, -PCH₂-, 4H) ppm; ¹³C NMR (CDCl₃, 100 MHz) δ 14.8 (d, $J_{\text{CP}} = 29.7\text{ Hz}$, -PCH₂-), 16.1 (s, -CH(CH₃)₂), 24.2 (d, $J_{\text{CP}} = 35.5\text{ Hz}$, -PCH-) ppm; ³¹P{¹H}NMR (CDCl₃, 161.9 MHz) δ +18.1 ($J_{\text{PB}} = 65.9\text{ Hz}$) ppm. HRMS (ESI). Calcd for C₁₀H₂₈B₂P₂ [M+H]⁺: 233.1925. Found 233.1926.

***trans*-2d-BH₃:** CCDC # 888065; 73% isolated yield; $R_f = 0.78$ (CH₂Cl₂ 100%, SiO₂); ¹H NMR (CDCl₃, 400 MHz) δ 0.40 (br q, $J_{\text{HB}} = 98.8\text{ Hz}$, -BH₃, 6H), 1.19 (d, $J_{\text{HP}} = 14.0\text{ Hz}$, -Bu', 18H), 1.88 (dd, $J = 9.7\text{ Hz}$, $J_{\text{HP}} = 20.8\text{ Hz}$, -PCH₂-, 4H), 2.36 (t, $J = 10.0\text{ Hz}$, -PCH₂-, 4H) ppm; ¹³C NMR (CDCl₃, 100 MHz) δ 12.9 (d, $J_{\text{CP}} = 29.2\text{ Hz}$, -PCH₂-), 24.8 (s, -PC(CH₃)₃), 27.2 (d, -PC(CH₃)₃, $J_{\text{CP}} = 32.9\text{ Hz}$) ppm; ³¹P{¹H}NMR (CDCl₃, 161.9 MHz) δ +26.6 ppm. HRMS (FAB). Calcd for C₁₂H₃₂B₂P₂ [M-H]⁺: 259.2087. Found

259.2086. Anal. Calcd for $C_{12}H_{32}B_2P_2$: C, 55.44; H, 12.41. Found: C, 55.45; H, 12.63.

trans-2e-BH₃: CCDC # 888061; 36% isolated yield; $R_f = 0.6$ (hexane/EtOAc: v/v = 4:1, SiO₂); ¹H NMR (CDCl₃, 400 MHz) δ 0.39 (br q, $J_{HB} = 101.0$ Hz, -BH₃, 6H), 1.29 (m, -C₆H₁₁, 12H), 1.61-2.02 (m, -PCH₂- and -C₆H₁₁, 14H), 2.24 (m, -PCH₂-, 4H), ppm; ¹³C NMR (CDCl₃, 100 MHz) δ 14.7 (d, $J_{CP} = 23.1$ Hz, -PCH₂-), 25.7, 25.8, 26.3, 26.4, 33.9 and 34.2 (-C₆H₁₂) ppm; ³¹P{¹H}NMR (CDCl₃, 161.9 MHz) δ +14.1 ($J_{PB} = 60.5$ Hz) ppm. HRMS (ESI). Calcd for $C_{16}H_{36}B_2P_2$ [M+Na]⁺: 335.2371. Found 335.2364. Anal. Calcd for $C_{16}H_{36}B_2P_2$: C, 61.59; H, 11.63. Found: C, 61.30; H, 11.63.

trans-2f-BH₃: CCDC # 888060; 39% isolated yield; $R_f = 0.30$ (CHCl₃/hexane: v/v = 1:1, SiO₂); ¹H NMR (CDCl₃, 400 MHz) δ 0.36 (br q, $J_{HB} = 106.4$ Hz, -BH₃, 6H), 1.69-1.84 (m, C-CH₂-C and P-CH₂, 28H), 2.04 (s, -CH-, 6H), 2.35 (m, -PCH₂-, 4H) ppm; ¹³C NMR (CDCl₃, 100 MHz) δ 11.3 (d, $J_{CP} = 29.7$ Hz, -PCH₂-), 27.6 (d, $J_{CP} = 9.1$ Hz, -P-C-), 30.2 (d, $J_{CP} = 34.6$ Hz, -PCH₂-), 35.7 and 36.5 (s, adamantyl) ppm; ³¹P{¹H}NMR (CDCl₃, 161.9 MHz) δ +19.6 ($J_{PB} = 76.8$ Hz) ppm. Anal. Calcd for $C_{24}H_{44}B_2P_2$: C, 69.26; H, 10.66. Found: C, 68.99; H, 10.74.

Synthetic details, spectral data, NMR spectra, and X-ray crystallographic data are shown in Supporting Information.

ACKNOWLEDGMENT

This work was partially supported by Grant-in-Aid for the Scientific Research on Innovative Areas of "Fusion Materials: Creative Development of Materials and Exploration of Their Function through Molecular Control" (No. 2206) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. H.I. and Y.O. appreciate Research Fellowships from the Japan Society for the Promotion of Science for Young Scientists.

REFERENCES

- (a) R. E. Weston, *J. Am. Chem. Soc.*, 1954, **76**, 2645; (b) R. D. Baechler and K. Mislow, *J. Am. Chem. Soc.*, 1970, **92**, 3090.
- (a) K. M. Pietrusiewicz and M. Zablocka, *Chem. Rev.*, 1994, **94**, 1375; (b) M. J. Johansson and N. C. Kann, *Mini-Rev. Org. Chem.*, 2004, **1**, 233; (c) A. Grabulosa, J. Granell, and G. Muller, *Coord. Chem. Rev.*, 2007, **251**, 25.
- (a) Y. Yamanoi and T. Imamoto, *Rev. Heteroatom Chem.*, 1999, **20**, 227; (b) K. V. L. Crepy and T. Imamoto, *Top. Curr. Chem.*, 2003, **229**, 1; (c) K. V. L. Crepy and T. Imamoto, *Adv. Synth. Catal.*, 2003, **345**, 79; (d) T. Imamoto, *J. Synth. Org. Chem. Jpn.*, 2007, **65**, 1060.
- A. R. Muci, K. R. Campos, and D. A. Evans, *J. Am. Chem. Soc.*, 1995, **117**, 9075.
- T. Imamoto, J. Watanabe, Y. Wada, H. Masuda, H. Yamada, H. Tsuruta, S. Matsukawa, and K.

- Yamaguchi, *J. Am. Chem. Soc.*, 1998, **120**, 1635.
6. Y. Morisaki, Y. Ouchi, K. Naka, and Y. Chujo, *Chem. Asian J.*, 2007, **2**, 1166.
 7. (a) Y. Morisaki, K. Suzuki, H. Imoto, and Y. Chujo, *Macromol. Rapid Commun.*, 2010, **31**, 1719; (b) H. Imoto, Y. Morisaki, and Y. Chujo, *Chem. Commun.*, 2010, **46**, 7542; (c) Y. Morisaki, K. Suzuki, H. Imoto, and Y. Chujo, *Macromol. Chem. Phys.*, 2011, **212**, 2603.
 8. Y. Morisaki, H. Imoto, Y. Ouchi, Y. Nagata, and Y. Chujo, *Org. Lett.*, 2008, **10**, 1489.
 9. (a) R. W. Alder and D. Read, *Coord. Chem. Rev.*, 1998, **176**, 113; (b) R. W. Alder, C. Ganter, C. J. Harris, and A. G. Orpen, *J. Chem. Soc., Chem. Commun.*, 1992, 1170; (c) R. W. Alder, D. D. Ellis, J. K. Hogg, A. Martín, A. G. Orpen, and P. N. Taylor, *Chem. Commun.*, 1996, 537; (d) R. W. Alder, C. Ganter, M. Gil, R. Gleiter, C. J. Harris, S. E. Harris, H. Lange, A. G. Orpen, and P. N. J. Taylor, *Chem. Soc., Perkin Trans. 1*, 1998, 1643.
 10. V. H. Gessner, S. Dilsky, and C. Strohmann, *Chem. Commun.*, 2010, **46**, 4719.
 11. (a) L. McKinstry and T. Livinghouse, *Tetrahedron Lett.*, 1994, **35**, 9319; (b) L. McKinstry and T. Livinghouse, *Tetrahedron*, 1994, **50**, 6145.
 12. A. B. Pangborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen, and F. J. Timmers, *Organometallics*, 1996, **15**, 1518.
 13. I. D. Gridnev, Y. Yamanoi, N. Higashi, H. Tsuruta, M. Yasutake, and T. Imamoto, *Adv. Synth. Catal.*, 2001, **343**, 118.